Epstein Secrets

imes.corn/2020/11/24/world/sputnik-vaccine-russia.html> (11124, Kramer, 18.61M) reports the manufacturers of the "leading Russian vaccine candidate" Sputnik V "said on Tuesday that it showed an efficacy rate of 95 percent in preliminary results from a clinical trial, which would put it at the same level

ance' German Marshall Fund of the U.S. online event, featuring Ukrainian Deputy Prime Minister for European and Euro-Atlantic Integration of Ukraine Olha Stefanishyna, Member of the European Parliament Anna Fotyga, New Europe Center Director Aylona Getmanchuk, and Georgian Institute for Strategic Studies co-found

tgoing Trump Administration." While the New York Times (11/24, Kramer, 18.61M) reports the manufacturers of the "leading Russian vaccine candidate" Sputnik V "said on Tuesday that it showed an efficacy rate of 95 percent in preliminary results from a clinical trial, which would put it at the same level

nce' German Marshall Fund of the U.S. online event, featuring Ukrainian Deputy Prime Minister for European and Euro-Atlantic Integration of Ukraine Olha Stefanishyna, Member of the European Parliament Anna Fotyga, New Europe Center Director Aylona Getmanchuk, and Georgian Institute for Strategic Studies co-found

uced Batch Of Sputnik V. Reuters (5/20) reports that Brazilian pharmaceutical company Uniao Quimica "completed production of its first batch of the Sputnik V coronavirus vaccine with active ingredients and technology supplied by Russia." Russia's Gamaleya Institute "said it had seen to quality control

ers include Lithuanian Foreign Affairs Minister Gabrielius Landsbergis, Deputy Prime Minister for European and Euro-Atlantic Integration of Ukraine Olha Stefanishyna, European Commission SGUA Acting Head Katarina Mathernova, and European Anti-Corruption Initiative to Ukraine Head of Programmes Eka Tkeshelashvili